Business Context and Reporting Period
This Form 8-K Current Report from Jaguar Health, Inc. (JAGX) covers events occurring between July 19, 2019, and July 23, 2019. The Company, an emerging growth company incorporated in Delaware, reported the pricing and closing of a registered public offering and the creation of a new series of preferred stock.
Key Financial Metrics and Capital Structure
Capital Raise: The Company completed a public offering on July 23, 2019, generating gross proceeds of $16.56 million. This amount included the full exercise of an over-allotment option by the underwriter, Ladenburg Thalmann & Co. Inc.
Securities Issued:
- Common Stock: 2,886,500 shares issued in the offering.
- Series B Preferred Stock: 10,787 shares issued as part of Class B Units.
- Warrants: Series 1 and Series 2 warrants to purchase up to 8,280,000 shares of Common Stock each (16,560,000 total warrants).
Outstanding Equity: As of July 23, 2019, the Company had 5,025,840 shares of Common Stock outstanding (excluding shares issuable upon conversion of preferred stock).
Financials: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes
Series B Convertible Preferred Stock: On July 22, 2019, the Company filed a Certificate of Designation creating Series B Convertible Preferred Stock.
- Ranking: Ranks on par with Common Stock regarding dividends and liquidation.
- Voting: Generally no voting rights, except to protect specific preferences.
- Conversion: Convertible at the holder's option into 500 shares of Common Stock per preferred share, subject to beneficial ownership limitations (4.99% or 9.99% cap).
Offering Structure: The offering consisted of Class A Units (Common Stock + 2 Warrants) and Class B Units (Series B Preferred Stock + 1,000 Warrants). The over-allotment option was fully exercised, increasing the total issuance of common stock and warrants.
Guidance, Outlook, and Risks
Warrant Expiration Conditions: The warrants issued in the offering have unique expiration triggers tied to clinical trial results and stock performance:
- Series 1 Warrants: Expire 5 years from issuance or 30 days after positive interim results from the HALT-D trial, provided the stock price exceeds 115% of the exercise price ($2.30) for 20 consecutive days with sufficient volume.
- Series 2 Warrants: Expire 5 years from issuance or 30 days after a pivotal Phase 3 trial for crofelemer (Mytesi) meets its primary endpoint, provided the stock price exceeds 150% of the exercise price ($3.00) for the measurement period with sufficient volume.
Exercise Price: All warrants have an exercise price of $2.00 per share.
Risks: The filing highlights the dilution potential from the warrants and the conversion of Series B Preferred Stock. The Company's future liquidity and operations depend on the success of its clinical trials, specifically regarding diarrhea treatment.
Investor Verification Checklist
- Verify the full terms of the Series B Preferred Stock in the Certificate of Designation (Exhibit 3.1).
- Review the specific conditions for warrant acceleration and expiration in the warrant agreements (Exhibits 4.1 and 4.2).
- Confirm the status of the HALT-D investigator initiated trial and the pivotal Phase 3 trial for crofelemer to assess warrant expiration timelines.
- Check subsequent filings for updates on the use of the $16.56 million in gross proceeds.
- Monitor the Company's cash position and burn rate, as this filing does not disclose current liquidity levels.